Literature DB >> 18571162

Rasagiline in neurodegeneration.

Anthony H V Schapira1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18571162     DOI： 10.1016/j.expneurol.2008.05.002

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


× No keyword cloud information.
  4 in total

Review 1.  Early versus delayed initiation of pharmacotherapy in Parkinson's disease.

Authors:  Matthias Löhle; Carl-Johan Ramberg; Heinz Reichmann; Anthony H V Schapira
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 2.  Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.

Authors:  Daphne Robakis; Stanley Fahn
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

3.  Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure.

Authors:  Sylvia Stemberger; Werner Poewe; Gregor K Wenning; Nadia Stefanova
Journal:  Exp Neurol       Date:  2010-05-21       Impact factor: 5.330

4.  Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.

Authors:  K Y Chau; J M Cooper; A H V Schapira
Journal:  Neurochem Int       Date:  2010-07-17       Impact factor: 3.921
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.